Liontrust Discloses 5.03% Stake in MaxCyte
Liontrust Investment Partners disclosed a 5.03% beneficial stake in MaxCyte in a Schedule 13D filed Oct. 15, 2026. The filing details September sales followed by purchases on Oct. 14.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.